Incubator at North Brunswick Graduates
Below is a sampling of some of the companies that have graduated from the Incubator at North Brunswick.
3D Biotek is a biotechnology company focusing on commercialization of novel 3-dimensional (3-D) cell culture devices for use in stem cell, cell biology, tissue engineering, drug discovery, and medical device fields.
Bright Cloud International Corp.
With academic roots in Rutgers University, Bright Cloud is a biomedical company focused in the fields of human-machine interface, virtual rehabilitation, remote rehabilitation, and integrative therapy. Its latest product, Bright Brainer, is a Class I FDA listed medical device that provides intensive game based motor training and cognitive exercising
Accelalox is a privately held company developing therapies to treat musculoskeletal conditions. Our initial therapy will accelerate and enhance bone healing. This therapy will be used for bone fractures and spinal fusions to improve patient outcomes through accelerated healing and reduced complications.
Actinobac Biomed is a spin-out from UMDNJ. Their focus is on development of pharmaceutical technologies based upon agents which target Leukocyte Function Antigen-1. The first targeted therapeutics is to treat hematologic malignancies such as leukemia, lymphoma, and myeloma.
In June 2011, Actinobac Biomed demonstrated in vivo efficacy for psoriasis treatment. Click here for more information.
Advaxis Inc. is a biotechnology company based upon the concept that in order to treat cancer and other diseases immunologically, it is best to use a modified infectious micro-organism to elicit the most profound immune response possible. It has been found that the unique microbe Listeria monocytogenes is capable of stimulating numerous aspects of the immune system simultaneously. Unlike other therapeutic approaches, Advaxis’ Listeria technology has been able to constantly demonstrate complete therapeutic responses resulting in complete tumor regression, even in the presence of immune tolerance. The company is the exclusive licensee of a broadly enabling platform technology for creating cancer vaccines and therapies for infectious diseases and other immune problems based upon genetically modified Listeria.
Aestus Therapeutics was founded in 2005 to take advantage of the vast amount of data created by high-throughput and genome-scale technologies. By integrating a broad spectrum of cutting edge technologies in novel ways, Aestus Therapeutics has intellectualized the pharmaceutical R&D process to create considerable value and new products for diseases with unmet medical needs.
Amicus Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule, orally administered drugs known as pharmacological chaperones, for the treatment of a range of human genetic diseases.
Amicus is focused on three key strategic priorities:
- The Phase 3 development of its lead program, AT1001 (migalastat HCl) for the treatment of Fabry disease;
- The advancement of pharmacological chaperones used in combination with enzyme replacement therapies (ERT) for the treatment of lysosomal storage diseases; and
- The advancement of its lead pre-clinical programs that utilize its pharmacological chaperone technology for the treatment of diseases of neurodegeneration.
Since its inception in 2002, Amicus has assembled a world-class leadership team with proven expertise in drug discovery, development and commercialization. The Company completed an Initial Public Offering in May 2007 and trades on the NASDAQ National Market under the Ticker Symbol: FOLD. Amicus’ headquarters is located in Cranbury, NJ and has a research facility in San Diego, CA.
Aucta Pharmaceuticals, LLC
Aucta Pharmaceuticals, LLC. (AUCTA, latin-improved, enhanced) is founded by experienced pharmaceutical research scientists from the U.S. and China, and managed by U.S. pharma industry veterans. The company is located in both China and New Jersey. Their expertise is new drug product development, product label improvement and solving difficult technical issues. They have solid fundamentals and sophisticated technology platform that can rapidly tackle technical issues and propose new product concept. The company will be in the business of novel and generic formulation product development. They work with pharma companies around the world for product co-development, sponsored research and provide value adding solutions to their partners and projects.
API Pharma Tech LLC
API Pharma Tech LLC is a research based technology development and drug substance, drug products manufacturing & marketing company operated by highly skilled and expert scientists and business strategists.
Angex Pharmaceuticals Inc.
Angex Pharmaceuticals is engaged in the discovery and development of innovative medicines to address the unmet medical needs for the improvement of human health.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. The mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need. They are currently developing three product candidates, two based on their proprietary pulsatile nitric oxide delivery device, which is referred to as INOpulse, and a third device which is referred to as bioabsorbable cardiac matrix, or BCM.
BioAegis Therapeutics Inc.
BioAegis Therapeutics Inc. is a clinical stage entity commercializing groundbreaking discoveries in inflammation and infection, directed at addressing serious diseases. The Company is pursuing a portfolio of high value indications based on repletion of plasma gelsolin, an integral and ubiquitous, natural human protein.
Biotecnol is a biopharmaceutical company focusing on the discovery, engineering and development of novel biopharmaceutical products. Most are multifunctional antibody molecules, directed to key therapeutic targets. Using its technologies, Biotecnol is developing a unique pipeline of products for applications in major disease areas. Enhancing antibodies’ efficacy by engineering multi-specificity via the creation of bi-specific antibody formats has emerged as a promising new wave in antibody.
Calyptus Pharmaceutical’s is a research and development company with a mission to improve lives of patients by increasing access and affordability of quality medicines.
Calyptus empower the healthcare system by delivering pharmaceutical solutions that bridge unmet needs, resolve technological complexity, create accelerated regulatory pathways and overcome market access barriers.
Calyptus is laying the foundations of a specialty pharmaceutical business serving the needs of hospitals, community clinics, specialty, and retail pharmacies by delivering a portfolio of sterile products.
Conversion Energy Enterprises (CEE)
CEE is a privately-held corporation that was formed to develop and prototype innovative laser products for medical applications. CEE also provides consulting services to large and small business clients in optoelectronics, lasers, sensors and advanced electronics.
The company’s focus is on utilization of a novel, proprietary, biocompatible, laser activated tissue adhesive that can be used as an alternative to sutures and staples with initial emphasis on hernia repair.
Celmatix Clinical Laboratories LLC (CCL)
Celmatix Clinical Laboratories LLC (CCL) manages the laboratory and testing functions of Celmatix’s next generation fertility test. Celmatix is a personalized medicine company focused on fertility and women’s health. The company leverages big data and genomics to create products that bring greater clarity to the treatment of infertility and pave the way for proactive fertility management. Founded in 2009 and headquartered in New York City, Celmatix is committed to empowering women with data driven insights about their reproductive healthChromocell
Chromocell is a drug discovery company focused on the identification and development of novel therapeutics against the most complex and challenging drug targets. Their therapeutic programs leverage the ability of Chromovert technology to rapidly create cell lines and assays that were previously out of reach. They focus on high value drug targets that require the creation of complex multi-gene cell lines or the establishment of large panels of related receptors to determine specificity. They work mainly in pain relief, anxiety treatment and respiratory disorders.
Chromovert technology helps overcome roadblocks and challenges in a broad range of biomedical research. Among the most promising applications is its ability to enrich populations for cell therapy — a critical need in the clinical utilization of this field. Chromovert cell engineering can also be applied in the areas of stem cells, biologics production and flavors research.
Crystal Pharmatech is a technology-driven contract research organization (CRO) that focuses on materials science and engineering for drug development. They partner with clients to ensure comprehensive solutions for their needs in solid-state research, crystallization process development, and preformulation studies. They guide clients in the discovery and selection of the optimal solid phase for drug development using all aspects of pre-formulation studies, including API process and formulation development, regulatory support and intellectual property protection.
Euprotein is a bioreagent company with a particular focus on developing recombinant proteins from mammalian cells for drug discovery applications. Euprotein also develops and implements mammalian cell based protein expression technology platforms for custom production services in support of biopharmaceutical drug development.
FluiDda Inc. is a spinoff company from the University of Antwerp whose main focus is developing imaging biomarkers to enhance drug development and patient care. These biomarkers combine biomedical imaging and advanced engineering methods resulting in a proprietary CT/CFD Pulmonary Imaging Technology that can be used as a diagnostic and research tool. The company technology has been validated in twenty clinical trials and has been focused on respiratory diseases such as asthma, COPD, and sleep apnea.GENEWIZ Inc.
GENEWIZ Inc.is a global contract research organization (CRO) committed to advancing research productivity through rapid delivery of reliable, high-quality results, competitive prices, excellent project management, and easily accessible award-winning technical support.
GENEWIZ customers are supported by major investments in state-of-the-art facilities, rigorous quality systems based on Good Laboratory Practices (GLP), and highly-qualified scientific teams at the local, national, and international levels. GENEWIZ continuously innovates and stays current with the latest technologies in order to produce the best results and most convenient customer experience.
Serving the life science community for 11 years, GENEWIZ, Inc. is the #1 provider of Sanger DNA sequencing services, as well as the partner of choice for gene synthesis, molecular biology, genomic, and GLP-compliant regulatory services. Excelling in both science and customer support, customers depends on GENEWIZ to take ownership of the research and to complete it faster and more cost-efficiently through their scale and specialized expertise. GENEWIZ is proud to help advance the research of tens of thousands of scientists at leading academic, pharmaceutical, clinical, biotechnology, and government institutions.
The mission of GENEWIZ is to contribute to the advancement of life sciences and technologies by making research more productive and cost efficient through their scalable services.
The vision is to make GENEWIZ the partner of choice for life science research communities around the world. Together they can make a difference in the pursuit of scientific discoveries, better medicines, a greener environment, and abundant healthy food supplies.
In June 2011, GENEWIZ, Inc. and Biomatters announced a strategic partnership to align DNA-based services and analysis software. Click here for more information on this partnership.
Genomic Prediction offers state-of-the-art preimplantation genetic testing services including amplification products, and testing for aneuploidy, single genedisorders and polygenic disorders.
Grace Therapeutics LLC
Grace Therapeutics LLC is a start-up life science company. Their goal is to develop improved formulations of select approved drugs including combination drugs for existing and/or additional therapeutic indications. They also intend to develop innovative drug delivery systems that improve the clinical outcome of currently marketed products. Their management team and network of consultant experts are experienced at founding and growing companies from the earliest stages of development through product approval and commercialization.
Hudson BioPharma, Inc.
Hudson BioPharma Inc. has incorporated in New Jersey and was created to develop anti-cancer medicines through utilization of their proprietary technology in the design and synthesis of drug leads targeting protein-to-protein interaction. The primary focus of Hudson BioPharma will be on utilizing tumor protein P53 (a natural tumor suppressor that regulates cell division by keeping cells from growing and dividing too fast or in an uncontrolled way), to develop an anti-cancer medicine.
Hurel Corporationprovides patented micro fluidic devices and cell culture that elevate the metabolic competency and endurance of cells cultured in vitro, and that simulate pharmacokinetic interactions among multiple tissues and organs. These proprietary capabilities produce unrivaled levels of physiologically relevant predictive sensitivity- “human relevance”- that define the current state of the art of hepatic and multi-tissue cell-based assays.
Ikano Therapeutics, Inc. (ITI)is a specialty pharmaceutical company focusing on developing innovative nasally delivered pharmaceutical products with a; particular focus on drugs treating pain and disorders related to the central nervous system. This is a later stage start-up company who has had periods of growth and stagnation while it was trying to refine its technology, create new products and seek funding to grow the business. ITI has a fully integrated nasal drug delivery platform combining proprietary formulation research, clinical and regulatory development, specialized delivery systems, sterile manufacturing and packaging of nasal products.
Ikano Therapeutics dissolved its business after transferring the ownership of their ITI-111 nasal midazolam program for the treatment of acute epileptic seizure to Upsher-Smith Laboratories Inc.
Innovera Pharmaceuticals specializes in the development of unique generic and branded products possessing development barriers. Innovera’s experience in developing challenging products including patent challenges and setting up vertically integrated pharmaceutical companies that manufacture active raw materials, finished dosage forms and sell the finished products. Innovera Pharmaceuticals is also developing improved formulations of select approved drugs including combination drugs for therapeutic indications.
Kamat Pharmatech, LLC
Kamat Pharmatech, LLC is a newly formed company that will operate as a contract research organization while developing its own technology focussing in the area of injectable products such as anti-inflammatory drugs that target autoimmune diseases.
Mito BioPharma is a biopharmaceutical company that focuses on targeting mitochondria and cellular metabolism modulation for development of therapeutics. Mitochondria are at the center of cellular metabolism and alteration in mitochondrial function contributes significantly to many diseases such as NASH, type 2 diabetes, lipid disorders, neurodegenerative diseases, cancer, and aging in general. It has long been proposed that these diseases could be effectively treated by modulating or correcting mitochondrial function. Mito BioPharma has a proprietary, small molecule-based technology and lead compounds that embody the therapeutic strategy of “correcting” or modulating such mitochondrial functions. The company expects this technology to have major impact on developing novel drugs in these therapeutic areas. Currently, the company is prioritizing liver-based diseases such as NASH, type 2 diabetes and certain liver-based orphan drug diseases. The company is currently in the lead finding phase with the anticipation of initiating IND-enabling studies in 2017. Moreover, the R&D team is generating an extended pipeline of candidate compounds suitable for other indications such as cancer and neurodegenerative diseases in order to capture the full value of its platform technology. Mito Biopharma’s core technology has been exclusively licensed from Rutgers University.
Nanion Technologies is a spin-off company from the Center of Nanoscience (CeNS) of the University of Munich (LMU). Nanion combines bio- and microtechnology in a company serving the life sciences industry by offering products and services which will dramatically increase the speed and efficiency of the drug discovery process in an important segment of the pharmaceutical market. Nanion bases its business on a proprietary chip technology and will design and develop High Throughput Screening (HTS) systems for ion channel active drugs (ICADs). Ion channels are prime targets for innovative medicines aimed at many important diseases.
Neurotez is a private corporation, formed to study and advance treatments for degenerative disorders of the central nervous system (CNS). Utilizing an integrated platform that spans activities from discovery to proof of concept clinical trials, Neurotez aims to identify and facilitate the commercialization of safe and efficacious CNS drugs. Neurotez’s lead biopharmaceutical is a potential therapeutic for Alzheimer’s disease patients, currently in the planning for clinical trials. Additional candidates, identified by exploiting proprietary screening technologies are in the discovery stage.
Nexomics Biosciences, Inc.
Nexomics Biosciences, Inc. is a Rutgers spinout focusing on the discovery, development and commercialization of novel drugs for cancer, antiviral and antibiotic treatments. Additionally, Nexomics Biosciences functions as a contract research organization (CRO), offering a broad array of gene-to-structure services to the biopharmaceutical community.
NJ Biopharmaceuticals LLC
NJ Biopharmaceuticals LLC (NJ Bio) is a Contract Research Organization geared towards providing comprehensive chemistry and biology services tobiopharmaceutical- and chemical-based technology companies. The company is located in the Commercialization Center for Innovative Technologies (CCIT), asignificant biotech incubator at North Brunswick in the heart of New Jersey’s “Research Corridor” with easy access to New Jersey and New York airports.
While the company has a strong background in synthetic organic chemistry and protein based biopharmaceuticals, it is a “differentiated” service provider with aniche in several areas including expertise in antibody-drug conjugates (ADCs), bioconjugation to proteins and biomaterials, linker chemistry design forconjugations, ADC constructs, and process development for small molecules and ADCs. At NJ Bio we are developing novel Protoxins which will serve as nextgeneration toxins for Antibody drug conjugates, expertise in multi-step customized flow chemistry synthetic routes for drug intermediates and APIs along with aunique offering to design custom flow chemistry equipment in collaboration with experts at Amar Equipment Pvt. Ltd., services to manufacture research-gradeprotein and antibodies, and ability to develop plate-based assays to evaluate the ability of compounds to promote or inhibit cell proliferation.
Novanex is a US-based medical device company that develops and commercializes innovative device and technology to monitor or detect disease conditions or status. Their first developmental product, OMC100, monitors and displays the blood glucose level non-invasively in two minutes. The system is designed for use in hospitals as well as in outpatient sites and homes.
NutraSorb, LLCpioneers the use of a proprietary, groundbreaking process that naturally concentrates the beneficial phytonutrients from fruits and vegetables into foods in amounts sufficient to promote health and wellness. The science-based, tasty, natural and shelf-stable functional foods and ingredients deliver an effective daily dose of antioxidants, polyphenols and other phytonutrients in a few servings, while reducing sugars and unwanted calories. NutrasorbTM technology is green and environmentally friendly, generating no waste or pollution. It was invented by leading researchers from major US universities, who joined forces to create a new generation of innovative, nutritional products for the benefit of humankind.
Orthobond is a privately held medical company developing surface modification technology that can be applied to virtually any synthetic material to produce a desired biological response. The Company’s covalently-bound-nano-technology withstands high sheer forces and repeated sterilization. Orthobond believes the technology will provide significant clinically measurable benefits for a wide array of implantable prostheses and diagnostic applications.
PCAsso is a research and development diagnostics company committed to the identification and development of novel medical diagnostic technologies.
PDS Biotechnology Corporation
PDS Biotechnology is harnessing the newly discovered properties of specific synthetic positively charged (cationic) lipids to develop a new generation of more versatile, simpler, safer and significantly more potent B- and T-cell activating vaccines. PDS’s proprietary Versamune™ platform nanotechnology when combined with T-cell antigens leads to superior cures for infection and cancer.
Pre-D Partners LLC (MitoManage)
Pre-D Partners LLC (MitoManage) is dedicated to improving the health and well-being of those battling pre-diabetes and its associated physical issues: managing blood sugar, weight control, vague pain and inflammation. Our team of scientists and healthcare professionals are globally recognized with more than forty years of experience in drug discovery and research. Our premier product offer, Pre-D, is a convenient, twice-daily, pharmaceutical-quality supplement program that when taken along with proper diet and exercise, may help to restore mitochondrial function by supporting healthy sugar metabolism.
QualComp Consulting Services
QualComp Consulting Services specializes in the application of effective quality systems for Pharmaceutical, Biotechnology and Medical Device companies. Using proven project management, risk management and design controls expertise, QualComp is a trusted partner in ensuring the safety and efficacy of your products.
QualComp Consulting Services was founded in 2008 and has since grown to include consultants located throughout the United States and Canada. Our team is comprised of experts who bring to our clients the application of compliant best industry practices.
SkinAxis, LLC is a biotechnology company providing unique research and development services for the pharmaceutical, biotechnology, chemical, and cosmetic industries involved with drug and active ingredient discovery. Their exclusive in-house technology provides important, reliable, and previously unobtainable data on human skin and lip responses for drug and active ingredient discovery.
Sophion Bioscience Inc.
Sophion Bioscience, Inc. is the US Subsidiary of Sophion Bioscience A/S (Denmark). Sophion Bioscience A/S was founded in July 2000, emerging from a successful research and development program at NeuroSearch. Sophion provides advanced products and integrated solutions for ion channel drug discovery. Sophion’s unique QPatch automated patch clamp system has integrated cell preparation and QPlate exchange facilities enabling several hours of unattended operation. The QPlate flow channel system enables fast liquid exchange and allows testing of multiple compounds or increasing concentrations on the same cell. The 48-channel QPatch HTX takes automated patch clamping to an even higher level. With its ability to generate thousands of high quality data points/day, QPatch HTX enables new screening paradigms in ion channel drug discovery and safety testing. The new QPatch 8/8X extends the QPatch family to six members.
In July 2011, Sophion Bioscience announced that it signed an agreement to join Biolin Scientific, a Swedish materials science company. Click here for more details on this agreement.
SunGen Pharma LLC
SunGen Pharma is a pharmaceutical company focused on the development and marketing of value added oral dose and injectable generic drugs primarily in the US.
Sunnylife Pharma Inc.
Founded by a team of former Merck scientists, Sunnylife Pharma Inc. is a research services organization providing drug discovery and development activities in the areas of medicinal chemistry, target validation, lead optimization and custom synthesis.
TAXIS Pharmaceutical is focused on pharmaceutical discovery and development of antimicrobials targeting drug-resistant bacterial pathogens. They are currently in the process of commercializing a novel class of small-molecule compounds based on exclusive worldwide rights to the IP jointly owned by Rutgers and UMDNJ.
TRIM-edicine is a biotechnology company developing novel biopharmaceutical products designed to treat a number of unmet medical needs in areas such as oral care, dermal injuries, microsurgery, sports medicine, and muscular dystrophy. Their technology is based on a series of molecular, biochemical, and animal model studies which led to the discovery of a novel protein named mitsuggumin53 (MG53) which represents the first known molecular component that is essential for the intrinsic cellular membrane repair process. MG53 is expressed exclusively in skeletal and cardiac tissues and provides a unique target for therapeutic interventions in systemic diseases of heart failure, muscular dystrophy, stress associated muscle injury, and age-related muscular atrophy. In non-muscle cells, MG53 has been shown to enhance the membrane repair function of a number of tissues including epithelial cells; therefore, the potential use for UV exposure, wrinkles, wounds, or burns is a strong possibility.
TRIM-edicine’s co-founder and chief scientific officer, Dr. Noah Weisleder, was awarded the prestigious 2011 Kauffman Foundation Outstanding Postdoctoral EntrepreneurAward. Click here for more information on this award.
Urigen Pharmaceuticals Inc.
Urigen Pharmaceuticals specializes in the design and implementation of innovative products for patients with urological ailments including, specifically, the development of innovative products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).
Vasade Biosciences, Inc.
Vasade Bioscience Inc. is a growth-stage biotechnology company committed to the pre-clinical discovery and development of cardio protective and vascular protective molecules, drugs, and devices for the prevention, treatment, and management of cardiovascular disease, the leading cause of death worldwide. By combining its unique expertise in animal models of cardiovascular diseases with state-of-the-arts genetic, genomic, and proteomic technologies. Vasade has positioned itself in the development of novel cardiovascular therapeutic drugs for the treatment of cardiac hypertrophy, coronary artery disease, myocardial infarction, and heart failure. Their development pipeline focuses on the rational discovery, design, and development of small molecules, peptides, and gene therapies targeting novel cell-signaling molecules that influence cardiac cell growth and survival.
VESAG Health Inc.
VESAG is a Mobile Personal Emergency Response System (MPERS) designed to track patient vitals, providing pre-emptive medical care and avoiding emergencies. The medical watch includes tracking features and collects patient parameters such as pulse, ECG/EKG, pulse, oxygen saturation, body weight, heart rate and blood pressure. All data is wirelessly transmitted to a web portal for monitoring by a medical call center. The device can be worn as a watch or a pendant and does not confine the wearer’s location due to the use of GPS and GSM technologies.
Visikol Inc is a biotechnology company which is focused on disrupting the bio-imaging field through leveraging its patent-pending chemical clearing agent Visikol®. The Visikol technology is an enabling technology which the company is utilizing to develop novel imaging platforms for developmental toxicology studies and 3-dimensional histology.